Analysts at HC Wainwright began coverage on shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) in a research report issued to clients and investors on Friday. The firm set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 39.08% from the company’s previous close.

A number of other research firms have also issued reports on PETX. BidaskClub lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Lake Street Capital lowered their target price on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Jefferies Group LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Aratana Therapeutics in a report on Friday, November 3rd. Finally, Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.75.

Shares of Aratana Therapeutics (NASDAQ PETX) opened at $7.19 on Friday. Aratana Therapeutics has a 52-week low of $4.97 and a 52-week high of $8.63. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The company had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The company’s quarterly revenue was up 1440.0% compared to the same quarter last year. During the same period last year, the company earned ($0.38) earnings per share. equities research analysts anticipate that Aratana Therapeutics will post -1.03 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/19/aratana-therapeutics-inc-petx-coverage-initiated-at-hc-wainwright.html.

In related news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.00, for a total value of $350,000.00. Following the transaction, the insider now directly owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the completion of the transaction, the chief operating officer now directly owns 70,267 shares in the company, valued at $429,331.37. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,000 shares of company stock valued at $785,600. 5.20% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Ray Gerald L & Associates Ltd. grew its holdings in shares of Aratana Therapeutics by 0.8% during the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 200 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 1,200 shares in the last quarter. American International Group Inc. grew its holdings in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,354 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 1,709 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Aratana Therapeutics by 6.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,875 shares in the last quarter. 73.39% of the stock is currently owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.